Nexiguran Ziclumeran
Neurodegenerative Disease
Intellia TherapeuticsPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Neurodegenerative Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dextromethorphan National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | B |
Hynr-Cs-Allo Hanyang University Seoul Hospital | Phase 1 | CC |
Same molecule, other indications
Nexiguran Ziclumeran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →